Zepbound for obstructive sleep apnea
How Zepbound (tirzepatide) is used in obstructive sleep apnea, what the clinical evidence shows, and how it compares to other treatment options.
Obstructive sleep apnea: what it is
Obstructive sleep apnea (OSA) is repetitive upper airway collapse during sleep, causing oxygen desaturation, sleep fragmentation, and daytime fatigue. Strongly linked to obesity and to cardiovascular morbidity. Prevalence: ~14% of men, ~5% of women in middle age; rising with obesity rates.
How Zepbound fits into obstructive sleep apnea treatment
First-line: continuous positive airway pressure (CPAP). Weight loss for overweight patients reduces severity dramatically. Tirzepatide (Zepbound) FDA-approved 2024 for OSA in adults with obesity. Mandibular advancement devices for mild-moderate disease or CPAP-intolerant. Upper airway surgery for selected anatomic abnormalities. Hypoglossal nerve stimulation for moderate-severe OSA who cannot use CPAP.
Zepbound works by: Tirzepatide is a dual incretin agonist: it hits both the GLP-1 receptor (like semaglutide) and the GIP receptor (which semaglutide doesn't). The combination produces stronger appetite suppression and better glycemic effect than GLP-1 alone, which translates to more weight loss in head-to-head trials (SURMOUNT studies showed ~20% body weight loss at the 15mg dose).
Who qualifies for Zepbound for obstructive sleep apnea
Same indications as Wegovy: BMI ≥30, or BMI ≥27 with a weight-related comorbidity. Contraindicated in personal/family history of medullary thyroid cancer or MEN2.
Clinical evidence
20.9% mean body-weight reduction at 72 weeks (15 mg dose)
Trial: SURMOUNT-1 (NCT04184622) · vs 3.1% with placebo · N = 2,539
How Zepbound compares to other obstructive sleep apnea treatments
Zepbound is the only drug in our catalog currently used for obstructive sleep apnea. See the Obstructive sleep apnea hub for additional treatment context.
Frequently asked about obstructive sleep apnea
- Can weight loss cure sleep apnea?
- Significant weight loss reduces or eliminates OSA in many patients with obesity-driven disease. The SURMOUNT-OSA trial showed tirzepatide (Zepbound) reduced AHI by ~50% and reversed OSA in ~43% of trial participants at one year. Weight loss is now FDA-recognized as an OSA treatment, not just a risk-factor intervention.
- What is the AHI and what numbers should I know?
- AHI = Apnea-Hypopnea Index, the average breathing disturbances per hour during sleep. 5-15 = mild OSA, 15-30 = moderate, >30 = severe. AHI under 5 with symptoms can still be clinically significant (upper airway resistance syndrome). Goal of treatment is typically AHI <5 on therapy.
- If I can't tolerate CPAP, what are my options?
- Auto-titrating PAP often improves tolerance over fixed-pressure CPAP. Mandibular advancement devices (oral appliances fit by a dentist) work well for mild-moderate disease. Inspire (hypoglossal nerve stimulator, implanted) is FDA-approved for moderate-severe OSA who fail CPAP. Surgery (UPPP, jaw advancement, tonsillectomy) is anatomy-specific. Weight loss with a GLP-1 is now an evidence-backed primary option for obesity-driven OSA.
- Why does OSA cause high blood pressure?
- Repeated nighttime hypoxia + arousal triggers sympathetic activation, raising blood pressure that persists into the day. OSA is the most common cause of refractory hypertension (HTN not controlled on 3+ medications including a diuretic). Treating OSA often reduces blood pressure and medication burden.